前房内注射雷珠单抗治疗晚期儿童玻璃体视网膜疾病
该回顾性观察性病例系列研究纳入13例(14眼)血管活动性升高的儿童玻璃体视网膜疾病患者,行前房内注射雷珠单抗。术后1个月14眼血管活动均下降,3个月时7眼消退、6眼持续、1眼复发,最终观察无并发症报告。作者认为该途径对玻璃体内或视网膜下注射不可行的病例可能可考虑,但需进一步研究明确获益与风险。
要点
- 前房内注射雷珠单抗后1个月,14眼中14眼视网膜血管活动性下降。
- 术后3个月,7眼血管活动消退、6眼持续、1眼复发,最终观察无并发症报告。
- 作者认为该途径在玻璃体内或视网膜下注射不可行时可能可考虑,但需进一步研究。
核心结论
- 这些发现支持使用前房内注射雷珠单抗来减少家族性渗出性玻璃体视网膜病变或早产儿视网膜病变或相关疾病中的视网膜血管异常的可能性,但需要进一步研究以了解更精确的获益和风险。
- 作者认为在玻璃体内或视网膜下注射不可行的情况下可考虑该方法,同时认识到这些发现的局限性且长期结局仍需监测。
研究设计与样本
- 该研究为回顾性观察性病例系列研究,在中国上海交通大学医学院附属新华医院开展。
- 研究纳入2023年1月至8月诊断为玻璃体视网膜疾病且表现出血管活动性升高的13例儿童共14眼。
- 干预为前房内注射雷珠单抗。
主要发现
- 13例患者中12例为男性,平均年龄4.6岁(范围1个月至9岁)。
- 6例诊断为家族性渗出性玻璃体视网膜病变,4例为牵牛花综合征,1例为早产儿视网膜病变,2例为原因不明的慢性视网膜脱离。
- 术后1个月随访时,14眼中14眼血管活动性下降。
- 术后3个月随访时,14眼中7眼血管活动性消退、6眼持续、1眼复发。
- 最终观察时,未报告并发症。
局限性
- 作者指出这些发现存在局限性,长期结局仍需监测。
- 作者指出需要进一步研究以了解更精确的获益和风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Anti-vascular endothelial growth factor (VEGF) treatment through intravitreal or subretinal administrations has been proven effective for VEGF-driven pediatric vitreoretinal diseases but are not feasible for advanced cases, such as shallow traction retinal detachments or peripheral circumferential retinal detachments which adhere to the lens. Intra-anterior chamber injection (IAcI) of anti-VEGF may be a viable alternative in such cases but needs evaluation. OBJECTIVE: To investigate the effects and safety of IAcI of anti-VEGF to treat VEGF-driven pediatric vitreoretinal diseases. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective observational case series study conducted at Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine in China. The study included 14 eyes of 13 children diagnosed with vitreoretinal disease exhibiting elevated vascular activity between January and August 2023. INTERVENTION: IAcI with ranibizumab. MAIN OUTCOMES AND MEASURES: Retinal vascular abnormalities, vitreous hemorrhage resolution, and complications 1 month and 3 months after injection. RESULTS: Of 13 patients included in this study, 12 were male. The mean age was 4.6 years (range, 1 month to 9 years). Six patients were diagnosed with familial exudative vitreoretinopathy, 4 with morning glory syndrome, 1 with retinopathy of prematurity, and 2 with chronic retinal detachments of unknown causes. At 1-month postoperative follow-up, vascular activity had decreased in 14 of 14 eyes. At 3-month follow-up, vascular activity had resolved in 7 of 14 eyes, persisted in 6 of 14 eyes, and reactivated in 1 of 14 eyes. On final observation, no complications were reported. CONCLUSIONS AND RELEVANCE: These findings support the possibility of treatment using IAcI with ranibizumab to decrease retinal vascular abnormalities in familial exudative vitreoretinopathy or retinopathy of prematurity or related conditions, but further studies are needed to understand more precise benefits and risks. This approach might be considered in cases where intravitreal or subretinal injection are not feasible, recognizing the limitations of these findings and that longer-term outcomes still need to be monitored.
引用
- Zhang W, Liu H, Chen Y, et al. Intra-Anterior Chamber Injection of Ranibizumab in Advanced Pediatric Vitreoretinal Diseases. JAMA Ophthalmol. 2024. PMID: 38236592. doi:10.1001/jamaophthalmol.2023.6198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。